Pekin Hardy Strauss Inc. Makes New $1.48 Million Investment in CRISPR Therapeutics AG $CRSP

07 Nov 2026, 16:51 by Tristan Rich · The Markets Daily

Pekin Hardy Strauss Inc. bought a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 26,775 shares of the company’s stock, valued at approximately $1,481,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Swiss National Bank lifted its stake in CRISPR Therapeutics by 5.1% in the 1st quarter. Swiss National Bank now owns 169,700 shares of the company’s stock worth $8,073,000 after purchasing an additional 8,200 shares in the last quarter. Affinity Asset Advisors LLC purchased a new position in shares of CRISPR Therapeutics during the first quarter valued at about $7,136,000. Congress Asset Management Co. grew its position in shares of CRISPR Therapeutics by 1.6% during the third quarter. Congress Asset Management Co. now owns 111,230 shares of the company’s stock valued at $6,153,000 after purchasing an additional 1,777 shares in the last quarter. KBC Group NV increased its holdings in shares of CRISPR Therapeutics by 3,999.9% in the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock worth $5,558,000 after purchasing an additional 113,997 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in shares of CRISPR Therapeutics by 29.6% in the first quarter. California State Teachers Retirement System now owns 101,232 shares of the company’s stock worth $4,816,000 after purchasing an additional 23,109 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 47,837 shares of the business’s stock in a transaction on Monday, October 19th. The shares were sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the transaction, the chief executive officer owned 311,899 shares in the company, valued at $15,526,332.22. The trade was a 13.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Simeon George sold 14,514 shares of the stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $49.63, for a total transaction of $720,329.82. Following the completion of the sale, the director directly owned 15,486 shares in the company, valued at approximately $768,570.18. This represents a 48.38% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 93,558 shares of company stock worth $4,881,663 in the last 90 days. 5.20% of the stock is currently owned by insiders.

CRISPR Therapeutics Price Performance

CRSP stock traded up $1.51 during trading on Friday, hitting $50.07. 1,234,187 shares of the company’s stock traded hands, compared to its average volume of 1,494,760. CRISPR Therapeutics AG has a 52 week low of $44.12 and a 52 week high of $63.45. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. The business has a fifty day simple moving average of $53.28 and a 200 day simple moving average of $52.81. The stock has a market capitalization of $4.84 billion, a price-to-earnings ratio of -10.56 and a beta of 1.92.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09). The business had revenue of $12.67 million during the quarter, compared to the consensus estimate of $14.75 million. CRISPR Therapeutics had a negative return on equity of 24.96% and a negative net margin of 1,812.07%. The business’s revenue was up 1311.1% on a year-over-year basis. As a group, research analysts expect that CRISPR Therapeutics AG will post -4.49 EPS for the current fiscal year.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

Positive Sentiment: Citigroup raised its price target on CRISPR Therapeutics, a potentially supportive signal for investor sentiment; the report did not provide the new target in the available details. Citigroup price target report
Positive Sentiment: Brookline Capital Markets substantially improved its forecasts, revising projected losses to $4.74 per share for FY2026 from $5.63 and to $3.83 for FY2027 from $4.51. HC Wainwright also made smaller upward adjustments to several quarterly and annual estimates and maintains a Buy rating. Better-than-previous forecasts could support the shares, although losses remain expected. Brookline Capital Markets comments CRISPR Therapeutics analyst estimates
Neutral Sentiment: RBC Capital assigned CRISPR Therapeutics a Hold rating, indicating a more cautious view than the Buy calls but not a direct downgrade. RBC Capital Hold rating
Neutral Sentiment: CRSP is attracting increased attention among Zacks.com users, but the “trending stock” coverage does not itself report a new business or clinical development. Zacks trending-stock article

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Citigroup boosted their target price on CRISPR Therapeutics from $88.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating on shares of CRISPR Therapeutics in a report on Friday, October 9th. Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Thursday, October 15th. Finally, UBS Group assumed coverage on CRISPR Therapeutics in a report on Thursday, October 15th. They set a “neutral” rating and a $52.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $69.69.

Check Out Our Latest Stock Report on CRISPR Therapeutics

About CRISPR Therapeutics

(Free Report)

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.